BenevolentAI
↗London, United Kingdom
BenevolentAI is a clinical-stage AI-enabled drug discovery company that uses artificial intelligence and machine learning to decipher complex disease biology and discover optimum therapeutic interventions. The company's proprietary Benevolent Platform leverages extracted and deduced biomedical information to design and develop new treatments for patients. Founded in 2013, BenevolentAI combines advanced AI technologies with scientific expertise to accelerate drug discovery timelines and improve success rates. The company operates in the TechBio space, applying deep learning and computational biology to generate novel drug candidates across multiple therapeutic areas including oncology, immunology, neurology, and rare diseases.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:AI-driven drug discovery, computational biology
SIZE & FINANCIALS
Employees:201-500
Revenue:$2.8M-$6.7M
Founded:2013
Ownership:private
Status:operating
FUNDING
Stage:Post-IPO Private
Total Raised:$378M
Investors:Temasek, Woodford Investment Management, Goldman Sachs, Other institutional investors
STOCK
Exchange:Delisted
Ticker:BAI (formerly listed on Euronext Amsterdam, delisted March 2025)
PIPELINE
Stage:Phase 1|Phase 2|Preclinical
Lead Drug Stage:Phase 1 (BEN-8744 ulcerative colitis)
Modalities:Small molecule, RARα/β agonist, PDE10 inhibitor, Pan-Trk antagonist
Active Trials:0
Trial Phases:Phase 1: 1 | Phase 2: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:AstraZeneca - Multi-year collaboration for target identification in CKD, IPF, heart failure, and SLE (since 2019, generated ~£32M revenue), Merck KGaA - Strategic collaboration for hit identification to preclinical stage for 3 targets in oncology, neurology/neuroinflammation, and immunology (~$500M in potential milestones), Novartis - Research and commercial collaborations, Eli Lilly - Technology partnership, Medicines for Malaria Venture (MMV) - Potential collaboration (referenced), DNDi - Collaboration on dengue drug discovery research
COMPETITION
Position:Leader
Competitors:Recursion Pharmaceuticals, Exscientia, Insilico Medicine, Atomwise, Healx, Deep Genomics, Valo Health, Owkin
LEADERSHIP
Key Executives:
Kenneth (Ken) Mulvany - Executive Chairman
Michael Brennan - Chief Strategy and Financial Officer, Executive Director
Ivan Griffin - Chief Business Officer, Co-Founder
Brent Gutekunst - Chief Development Officer, Co-Founder
Catherine Isted - Chief Financial Officer
Christina Busmalis - Chief Revenue Officer
Peter Allen - Deputy Chairman
Scientific Founders:Kenneth Mulvany, Michael Brennan, Ivan Griffin, Brent Gutekunst
Board Members:Kenneth Mulvany (Executive Chairman), Michael Brennan (Executive Director), Peter Allen (Deputy Chairman), Nigel Shadbolt (Non-Executive Director, joined July 2020)
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with BenevolentAI. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.